Featured Tickers:
Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Intra-Cellular Therapies, Inc. or Corcept Therapeutics Incorporated because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Intra-Cellular Therapies, Inc. and Corcept Therapeutics Incorporated compare based on key financial metrics to determine which better meets your investment needs.
About Intra-Cellular Therapies, Inc. and Corcept Therapeutics Incorporated
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder. In addition, the company develops lenrispodun (ITI-214) in Phase 2 clinical trial for the treatment of Parkinson’s disease; ITI-1284-ODT-SL in Phase 2 trial for the treatment of generalized anxiety disorder, and psychosis and agitation in patients with Alzheimer’s disease; ITI-1020 in Phase 1 trial for cancer immunotherapy; and ITI-1549 in preclinical studies for mood and anxiety disorders. It distributes its products through third-party wholesale drug distributors. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in Bedminster, New Jersey.
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Latest Pharmaceuticals and Intra-Cellular Therapies, Inc., Corcept Therapeutics Incorporated Stock News
As of April 1, 2025, Intra-Cellular Therapies, Inc. had a $14.0 billion market capitalization, compared to the Pharmaceuticals median of $173.7 million. Intra-Cellular Therapies, Inc.’s stock is up 57.9% in 2025, up 0.1% in the previous five trading days and up 90.56% in the past year.
Currently, Intra-Cellular Therapies, Inc. does not have a price-earnings ratio. Intra-Cellular Therapies, Inc.’s trailing 12-month revenue is $680.9 million with a -11.0% net profit margin. Year-over-year quarterly sales growth most recently was 50.8%. Analysts expect adjusted earnings to reach $0.126 per share for the current fiscal year. Intra-Cellular Therapies, Inc. does not currently pay a dividend.
As of April 1, 2025, Corcept Therapeutics Incorporated had a $9.7 billion market cap, putting it in the 80th percentile of all stocks. Corcept Therapeutics Incorporated’s stock is up 82.4% in 2025, up 57.6% in the previous five trading days and up 264.95% in the past year.
Currently, Corcept Therapeutics Incorporated’s price-earnings ratio is 74.7. Corcept Therapeutics Incorporated’s trailing 12-month revenue is $675.0 million with a 20.9% net profit margin. Year-over-year quarterly sales growth most recently was 34.3%. Analysts expect adjusted earnings to reach $1.910 per share for the current fiscal year. Corcept Therapeutics Incorporated does not currently pay a dividend.
How We Compare Intra-Cellular Therapies, Inc. and Corcept Therapeutics Incorporated Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Intra-Cellular Therapies, Inc. and Corcept Therapeutics Incorporated’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions